Literature DB >> 20935648

IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46.

Maya Eisenring1, Johannes vom Berg, Glen Kristiansen, Elisabeth Saller, Burkhard Becher.   

Abstract

The potent tumoricidal activity of interleukin 12 (IL-12) is thought to be mediated by the activation and polarization of natural killer (NK) cells and T helper type 1 (T(H)1) cells, respectively. By systematic analysis of the IL-12-induced immune response to subcutaneous melanoma (B16), we found that tumor suppression was mediated independently of T lymphocytes or NK cells. IL-12 initiated local antitumor immunity by stimulating a subset of NKp46(+) lymphoid tissue-inducer (LTi) cells dependent on the transcription factor RORγt. The presence of these NKp46(+) LTi cells induced upregulation of adhesion molecules in the tumor vasculature and resulted in more leukocyte invasion. Thus, this innate cell type is responsive to IL-12 and is a powerful mediator of tumor suppression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20935648     DOI: 10.1038/ni.1947

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  49 in total

Review 1.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

2.  Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo.

Authors:  Christian A J Vosshenrich; Thomas Ranson; Sandrine I Samson; Erwan Corcuff; Francesco Colucci; Eleftheria E Rosmaraki; James P Di Santo
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

3.  The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent.

Authors:  M J Smyth; M Taniguchi; S E Street
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

4.  Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

Authors:  Amit A Lugade; James P Moran; Scott A Gerber; Robert C Rose; John G Frelinger; Edith M Lord
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

5.  Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.

Authors:  Ronald J Buckanovich; Andrea Facciabene; Sarah Kim; Fabian Benencia; Dimitra Sasaroli; Klara Balint; Dionysios Katsaros; Anne O'Brien-Jenkins; Phyllis A Gimotty; George Coukos
Journal:  Nat Med       Date:  2008-01-06       Impact factor: 53.440

6.  IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors.

Authors:  Naoko Satoh-Takayama; Sarah Lesjean-Pottier; Paulo Vieira; Shinichiro Sawa; Gerard Eberl; Christian A J Vosshenrich; James P Di Santo
Journal:  J Exp Med       Date:  2010-02-08       Impact factor: 14.307

7.  Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46.

Authors:  Thierry Walzer; Mathieu Bléry; Julie Chaix; Nicolas Fuseri; Lionel Chasson; Scott H Robbins; Sébastien Jaeger; Pascale André; Laurent Gauthier; Laurent Daniel; Karine Chemin; Yannis Morel; Marc Dalod; Jean Imbert; Michel Pierres; Alessandro Moretta; François Romagné; Eric Vivier
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

Review 8.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

9.  Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

Authors:  Adil I Daud; Ronald C DeConti; Stephanie Andrews; Patricia Urbas; Adam I Riker; Vernon K Sondak; Pamela N Munster; Daniel M Sullivan; Kenneth E Ugen; Jane L Messina; Richard Heller
Journal:  J Clin Oncol       Date:  2008-11-24       Impact factor: 44.544

10.  OX40 ligand and CD30 ligand are expressed on adult but not neonatal CD4+CD3- inducer cells: evidence that IL-7 signals regulate CD30 ligand but not OX40 ligand expression.

Authors:  Mi-Yeon Kim; Graham Anderson; Andrea White; Eric Jenkinson; Wiebke Arlt; Inga-Lill Martensson; Lena Erlandsson; Peter J L Lane
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

View more
  88 in total

Review 1.  Tissue-Resident Cytolytic Innate Lymphocytes in Cancer.

Authors:  Briana G Nixon; Ming O Li
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

Authors:  Ling Zhang; Sid P Kerkar; Zhiya Yu; Zhili Zheng; Shicheng Yang; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

Review 3.  Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Authors:  Juming Yan; Mark J Smyth; Michele W L Teng
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

4.  Proton irradiation augments the suppression of tumor progression observed with advanced age.

Authors:  Afshin Beheshti; Michael Peluso; Clare Lamont; Philip Hahnfeldt; Lynn Hlatky
Journal:  Radiat Res       Date:  2014-02-25       Impact factor: 2.841

5.  The brave new world of innate lymphoid cells.

Authors:  Gérard Eberl; James P Di Santo; Eric Vivier
Journal:  Nat Immunol       Date:  2015-01       Impact factor: 25.606

Review 6.  IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

Authors:  Michele W L Teng; Edward P Bowman; Joshua J McElwee; Mark J Smyth; Jean-Laurent Casanova; Andrea M Cooper; Daniel J Cua
Journal:  Nat Med       Date:  2015-06-29       Impact factor: 53.440

Review 7.  The biology of innate lymphoid cells.

Authors:  David Artis; Hergen Spits
Journal:  Nature       Date:  2015-01-15       Impact factor: 49.962

8.  CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis.

Authors:  Sara Trabanelli; Antonio Curti; Mariangela Lecciso; Bérengère Salomé; Carsten Riether; Adrian Ochsenbein; Pedro Romero; Camilla Jandus
Journal:  Haematologica       Date:  2015-02-20       Impact factor: 9.941

Review 9.  New insights into IL-12-mediated tumor suppression.

Authors:  S Tugues; S H Burkhard; I Ohs; M Vrohlings; K Nussbaum; J Vom Berg; P Kulig; B Becher
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

10.  Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells.

Authors:  I H Chan; R Jain; M S Tessmer; D Gorman; R Mangadu; M Sathe; F Vives; C Moon; E Penaflor; S Turner; G Ayanoglu; C Chang; B Basham; J B Mumm; R H Pierce; J H Yearley; T K McClanahan; J H Phillips; D J Cua; E P Bowman; R A Kastelein; D LaFace
Journal:  Mucosal Immunol       Date:  2013-11-27       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.